Understand the source comparison
TB-4 Cardiac Protocol: Dosing Schedule Comparison
Acute Post-MI Recovery 8–10mg Twice weekly 8 weeks 128–160mg Administered within 72 hours of myocardial infarction to maximise border-zone salvage and neovascularisation during peak remodeling phase Chronic Heart Failure Support 4–6mg 12 weeks 96–144mg Used in
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute Post-MI Recovery
- 8–10mg
- Twice weekly
- 8 weeks
- 128–160mg
- Administered within 72 hours of myocardial infarction to maximise border-zone salvage and neovascularisation during peak remodeling phase
- Chronic Heart Failure Support
- 4–6mg
- 12 weeks
- 96–144mg
- Used in stable HFrEF patients (EF 30–45%) to support microvascular density and reduce fibrotic progression
- Preventive Cardiovascular Maintenance
- 2–4mg
- Once weekly
- Ongoing
- 8–16mg/month
- Explored in high-risk populations (family history, metabolic syndrome) without active disease. Evidence limited to animal models
- Veterinary Canine Dilated Cardiomyopathy
- 5mg (standardised)
- 6 weeks
- 60mg
- Used in Dobermans and Boxers with confirmed DCM. Peer-reviewed outcomes show 18–22% improvement in fractional shortening at 42 days